Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.
Volatility & Risk
Co-Diagnostics has a beta of -0.85, indicating that its share price is 185% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Co-Diagnostics and Lucid Diagnostics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Co-Diagnostics | 0 | 1 | 0 | 0 | 2.00 |
Lucid Diagnostics | 0 | 0 | 3 | 0 | 3.00 |
Valuation & Earnings
This table compares Co-Diagnostics and Lucid Diagnostics’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Co-Diagnostics | $6.81 million | 5.74 | -$35.33 million | ($1.32) | -0.95 |
Lucid Diagnostics | $2.43 million | 17.69 | -$52.67 million | ($1.27) | -0.65 |
Co-Diagnostics has higher revenue and earnings than Lucid Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Co-Diagnostics and Lucid Diagnostics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Co-Diagnostics | -582.36% | -42.35% | -38.55% |
Lucid Diagnostics | -1,576.60% | -901.79% | -106.33% |
Insider and Institutional Ownership
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 2.4% of Co-Diagnostics shares are held by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Lucid Diagnostics beats Co-Diagnostics on 9 of the 14 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.